ImageneBio (IMA) Depreciation & Amortization (CF) (2020 - 2025)
ImageneBio (IMA) posted Depreciation & Amortization (CF) of $87000.0 for Q2 2025, up 4250.0% sequentially from $2000.0 in Q1 2025, and down 5.43% YoY from $92000.0 in Q2 2024.
ImageneBio (IMA) Depreciation & Amortization (CF) (2020 - 2025) Analysis & Trends
ImageneBio has reported Depreciation & Amortization (CF) for 6 years, with the latest figure at $87000.0 in Q2 2025.
- Quarterly Depreciation & Amortization (CF) fell 5.43% year-over-year to $87000.0 in Q2 2025, while the trailing twelve-month figure through Dec 2025 was $89000.0 (down 82.2% YoY) and the FY2024 annual result came in at $500000.0, down 50.98% from the prior year.
- Depreciation & Amortization (CF) advanced to $87000.0 in Q2 2025 per IMA's latest filing, from $2000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $305000.0 in Q4 2023 and troughed at $2000.0 in Q1 2025.
- A 5-year average of $156833.3 and a median of $155500.0 in 2021 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2021 and 2025: Depreciation & Amortization (CF) jumped 117.33% in 2021, then slumped 99.09% in 2025.
- Over 5 years, Depreciation & Amortization (CF) stood at $163000.0 in 2021, then grew by 28.83% to $210000.0 in 2022, then surged by 45.24% to $305000.0 in 2023, then plunged by 67.54% to $99000.0 in 2024, then dropped by 12.12% to $87000.0 in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $87000.0, $2000.0, and $99000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | ImageneBio | 47.79 Mn | -87.56 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 2,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 87,000.00 |
| Jun 30, 2025 | 87,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2024 | 99,000.00 |
| Dec 31, 2024 | 99,000.00 |
| Sep 30, 2024 | 90,000.00 |
| Sep 30, 2024 | 90,000.00 |
| Jun 30, 2024 | 92,000.00 |
| Jun 30, 2024 | 92,000.00 |
| Mar 31, 2024 | 219,000.00 |
| Mar 31, 2024 | 219,000.00 |
| Dec 31, 2023 | 305,000.00 |
| Dec 31, 2023 | 305,000.00 |
| Sep 30, 2023 | 242,000.00 |
| Sep 30, 2023 | 242,000.00 |
| Jun 30, 2023 | 242,000.00 |
| Jun 30, 2023 | 242,000.00 |